NHS patients with rare blood disorders gain access to Ultomiris
Around 270 people with PNH and 160 people with aHUS will be eligible for the new treatment
Read More
Tag: paroxysmal nocturnal haemoglobinuria
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
